Arrow's A-689 enters preclinical development
Arrow Therapeutics, a London, UK-based antiviral drug discovery and development company, says that a further hepatitis C compound, A-689, has entered full preclinical development.
The agent is the second compound from Arrow's broad approach to the NS5a target to enter development. November 2006 saw Arrow's first hepatitis C compound, A-831, enter Phase I trials. Both compounds target the novel NS5a protein but have completely different chemical structures and bind to the target at different sites.
Once again, A-689 originates from Arrow's focused chemical library and was optimized in-house. The compound has shown highly potent activity in the replicon assay and has an excellent therapeutic index and good pharmacokinetic properties. Phase I trials on A-689 are planned for the second half of 2007, the firm noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze